Fulcrum Asset Management LLP increased its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) by 3,648.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,622 shares of the company’s stock after buying an additional 5,472 shares during the period. Fulcrum Asset Management LLP’s holdings in TransMedics Group were worth $473,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also recently bought and sold shares of TMDX. Allspring Global Investments Holdings LLC boosted its stake in TransMedics Group by 4.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 6,977 shares of the company’s stock worth $549,000 after purchasing an additional 322 shares during the last quarter. 180 Wealth Advisors LLC grew its stake in shares of TransMedics Group by 14.1% in the 3rd quarter. 180 Wealth Advisors LLC now owns 4,745 shares of the company’s stock valued at $396,000 after buying an additional 588 shares during the period. Putney Financial Group LLC purchased a new position in TransMedics Group in the third quarter worth approximately $161,000. Trek Financial LLC purchased a new position in shares of TransMedics Group during the 3rd quarter worth $11,989,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of TransMedics Group by 700.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 800 shares of the company’s stock valued at $67,000 after acquiring an additional 700 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.
TransMedics Group Price Performance
TMDX stock opened at $91.38 on Monday. The company’s 50 day simple moving average is $80.28 and its 200-day simple moving average is $92.05. The firm has a market capitalization of $3.17 billion, a PE ratio of 24.76, a P/E/G ratio of 1.62 and a beta of 2.14. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.53 and a quick ratio of 4.15. TransMedics Group, Inc. has a 12 month low of $60.10 and a 12 month high of $156.00.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.51 earnings per share for the quarter, topping the consensus estimate of $0.30 by $0.21. The company had revenue of $203.01 million during the quarter, compared to the consensus estimate of $178.06 million. TransMedics Group had a return on equity of 13.30% and a net margin of 19.85%. TransMedics Group’s revenue was up 41.1% compared to the same quarter last year. During the same quarter last year, the business posted $0.66 earnings per share. Equities analysts expect that TransMedics Group, Inc. will post 1.66 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other TransMedics Group news, Director David Weill purchased 1,336 shares of the business’s stock in a transaction on Friday, September 11th. The stock was bought at an average cost of $81.63 per share, for a total transaction of $109,057.68. Following the acquisition, the director owned 16,392 shares of the company’s stock, valued at approximately $1,338,078.96. The trade was a 8.87% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 6.90% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on the company. TD Cowen reaffirmed a “buy” rating and issued a $120.00 price objective on shares of TransMedics Group in a research note on Tuesday, September 8th. Barclays started coverage on TransMedics Group in a research report on Wednesday, October 7th. They set an “overweight” rating and a $120.00 target price on the stock. Canaccord Genuity Group upped their price objective on TransMedics Group from $95.00 to $120.00 and gave the company a “buy” rating in a research note on Friday, November 6th. Zacks Research upgraded shares of TransMedics Group from a “strong sell” rating to a “hold” rating in a research note on Monday, November 2nd. Finally, Wall Street Zen raised TransMedics Group from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Five investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, TransMedics Group currently has a consensus rating of “Hold” and an average target price of $113.30.
Read Our Latest Analysis on TMDX
TransMedics Group Company Profile
TransMedics Group, Inc. is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services. The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.
Further Reading
- Five stocks we like better than TransMedics Group
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX – Free Report).
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.
